The resulting compound (compound 19, containing an acrylamide moiety) exhibited the highest in vitro activity, selectively inhibiting both normal and cancer cells (LO2 IC50 = 23.39 μM; MDA-MB-231 IC50 = 1.54 μM), and showed strong inhibition of both AURKA and AURKB (AURKA IC50 = 1.7 nM). Here, AURKA is linked to cancer.